Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Royal Bank of Canada

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “outperform” rating reissued by investment analysts at Royal Bank of Canada in a report released on Wednesday,Benzinga reports. They currently have a $8.00 price target on the stock.

A number of other research analysts have also commented on PYXS. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Performance

PYXS stock traded up $0.01 during trading on Wednesday, hitting $1.07. 67,231 shares of the company traded hands, compared to its average volume of 751,319. The firm has a market capitalization of $63.33 million, a PE ratio of -1.03 and a beta of 1.11. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18. The company has a 50-day moving average of $1.35 and a 200-day moving average of $2.40.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. ProShare Advisors LLC bought a new position in Pyxis Oncology in the 4th quarter worth $26,000. Caption Management LLC purchased a new position in Pyxis Oncology in the fourth quarter worth about $35,000. Ameriprise Financial Inc. purchased a new position in Pyxis Oncology in the fourth quarter worth about $35,000. Commonwealth Equity Services LLC grew its position in Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new position in Pyxis Oncology in the fourth quarter worth about $47,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.